Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | SPR | P35270 | 3/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.40 |
| ▸ | ASPH | Q12797 | 2/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801309 | 0.91 | ADORA3 (0.39) | ADORA3ADORA2AADORA1SPRKDM4E | |
| SCHEMBL2803183 | 0.90 | SPR (0.38) | ADORA3ADORA2AADORA1SPRKDM4E | |
| SCHEMBL2800936 | 0.86 | STAT6 (0.42) | ADORA3ADORA2AADORA1SPRKDM4C | |
| SCHEMBL2801745 | 0.84 | SPR (0.41) | SPRKDM4CASPHKDM8KDM4E | |
| SCHEMBL2802021 | 0.81 | SPR (0.41) | SPRKDM4CKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL2801219 | 0.81 | VNN1 (0.48) | KDM4C | |
| SCHEMBL2801085 | 0.80 | PDE4B (0.44) | SPRKDM4ESIRT5ALDH1A1L3MBTL1 | |
| SCHEMBL2801102 | 0.80 | SIRT5 (0.50) | SPRSIRT5ALDH1A1L3MBTL1HPGD | |
| SCHEMBL2798414 | 0.80 | STAT6 (0.43) | ADORA3ADORA2AADORA1SPRKDM4C | |
| SCHEMBL2801054 | 0.80 | CCR1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206714-B1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8729264-B2 | Agent for prevention and/or treatment of skin diseases | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-05-20 | — | — | US | disclosed |
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2206714-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | Kyowa Hakko Kirin Co., Ltd. (JP) | 2010-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256134-A1 | AGENT FOR PREVENTION AND/OR TREATMENT OF SKIN DISEASES | TYR, CUTA, SERPINB1 | ADORA3 3783/4885ADORA2A 4017/4885ADORA1 2960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.